Clinical Trial Search

Primary: Recurrent VH Incidence (Early and Late) — 22.2; 10.8; 32.4; 11.1 Percentage of participants — p=<0.05

Primary: Change From Baseline in BCVA (Best Corrected Visual Acuity) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation…

Primary: Rate of Resolved Post-operative Vitreous Hemorrhage. — 6; 5 Participants

Primary: Visual Acuity — 0.32; 0.44 logMAR units

Primary: Treatment or "Failure" Defined as Vitrectomy — 12; 17 percentage of participants — p=0.37

Primary: Best Corrected Visual Acuity — 1.1; 1.4 LogMar

Primary: Positive Culture — 8 percentage of patients

Primary: Efficacy of the Treatment Assessed With Visual Acuity Measured by ETDRS Charts. — 0.18; 0.36; 0.18 logMAR

Primary: Number of Participants Who Preferred Subconjunctival Anesthetic at the Third Follow-up Visit — 50 participants

Primary: The Response of Intravitreal Avastin in Causing a Clinically Significant Reduction in Uveal Melanoma Tumor Size (Base Height and Volume). — 1; 0; 0; 0 participants

Primary: Number of Participants (or Chart Reviews) With Complete Success of Primary Vitrectomy Surgery — 92; 169 Participants

Primary: Proportion of Subjects With Recurrence of Uveitis in the Study Eye and Overall Summary of Number of Participants With Ocular Treatment-Emergent Adverse Events for the…

Primary: Reoperation — 1; 7 participants — p=0.033

Primary: Total Number of Intravitreal Injections Over a 12 Month Period — 8.7; 9.5 injections

Primary: Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Adhesion at Day 28 — 25.3; 6.2 percentage of participants — p=<0.001

Primary: The Effect of Intravitreal Bevacizumab Injections on Rate of Recurrent Retinal Detachment (Increase or Decrease) — 6 Participants

Primary: E-ETDRS Visual Acuity Letter Score (Area Under the Curve From Baseline) — 59.3; 63.0 units on a scale

Primary: Macular Function Using Microperimetry — 2.7; 12.7; 4.2; 10.7 dB

Primary: Reduction in Macular Edema — 15; 8; 4 Participants

Primary: Mean Change in Central 1 mm Subfield Thickness Between Baseline and 9 Months — -51; -60 millimeters

Primary: Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Adhesion at Day 28. — 27.9; 13.1 percentage of participants — p=0.003

Primary: Proportion of Patients Achieving Total Posterior Vitreous Detachment (PVD) Without Creation of an Anatomical Defect — 13.8; 18.2; 31.3; 10 percentage of participants…

Primary: Vision — 0.16 logMAR

Primary: BCVA — 0.8; -0.3; -1.8 Letters

Primary: Mean Central Subfield Thickness (CST) — 422.9; 419.7; 364.5; 346.7 microns

Primary: Best Corrected Visual Acuity Change From Baseline at All Visits — 10.5; 15.1 ETDRS letters

Primary: Change From Baseline in Central Retinal Thickness in the Study Eye — 403.4; -38.9 Microns

Primary: Number of Lucentis® Injections Up To And Including Week 52 — 2.64; 2.44; 3.73 Injections

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation…

Primary: Maximum Concentration (Cmax) of Anti-VEGF Antibody — 25.22; 9.56 ng/mL